This condition is a common side effect of chemotherapy. Severe myelosuppression, called myeloablation, can be fatal. The body’s bone marrow produces three types of cells: white blood cells, red blood cells, and platelets. Metabolic fate of chloroquine Benefits of taking plaquenil Stopping hydroxychloroquine abruptly Others include skin rashes and neuromyopathy. Some less common side affects include anemia, leukopenia, and thrombocytopenia due hydroxychloroquine’s effect on bone marrow, seizures, angioedema, bronchospasm, exfoliative dermatitis, Steven Johnson Syndrome, and psoriasis exacerbations. Feb 19, 2020 Plaquenil hydroxychloroquine is an antimalarial medication used to treat or prevent malaria, a disease caused by parasites, which enter the body through the bite of a mosquito. Plaquenil is also used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. Hydroxychloroquine HCQ is a disease-modifying anti-rheumatic drug DMARD typically used for the treatment of various rheumatic and dermatologic diseases. Three studies of HCQ in OA, including one abstract and one letter, are available and use a wide variety of outcome measures in small patient populations. A decrease in all three types of blood cells is referred to as pancytopenia. It can cause an oxygen shortage and other immune issues. Myelosuppression can decrease some or all of these. Hydroxychloroquine bone marrow suppression Bone marrow suppression - Wikipedia, Side Effects of Plaquenil Hydroxychloroquine, Warnings, Uses Chloroquine side effects depression Patients treated with hydroxychloroquine should be warned about the risk of hypoglycaemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycaemia during treatment with hydroxychloroquine should have their blood glucose level checked and treatment reviewed as necessary. Plaquenil and bone marrow. DailyStrength. Hydroxychloroquine in patients with inflammatory and.. Managing patients taking DMARDs - BMJ. PLAQUENIL hydroxychloroquine sulfate tablets is indicated for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, in patients who have not responded satisfactorily to drugs with less potential for serious side effects. Serious vision disturbances- changes to retina and cornea, bone marrow suppression, cardiomyopathy Interactions Hydroxychloroquine may increase the levels/effects of beta blockers, cardiac glycosides, hypoglycaemia associated agents, QTc prolonging agents T he levels/effects of hydroxychloroquine may be decreased by quinolone antibiotics Given this presentation, severe bone marrow suppression accompanying pulmonary infection and hemorrhage of the digestive tract associated with MTX and LEF combination therapy was diagnosed. Combination therapy of MTX and LEF was stopped, and celecoxib was also suspended because of possible liver toxicity.